According to Aptar Pharma, parent company of OINDP-focused CRO Nanopharm, the UK Medicines and Healthcare Products Regulatory Agency has completed an inspection of Nanopharm’s facility in Cwmbran, Wales and has certified the location as GMP compliant. In December 2021, Nanopharm announced its plans to move to the 25,000 sq ft site, including plans for cGMP laboratories.
Nanopharm offers development and analytical services for a wide range of inhaled and nasal drug delivery. In April 2025, the company announced that it was initiating a clinical study to validate its SmartTrack in-vitro-in-silico modeling platform for bioequivalence studies of inhaled drug products.
Nanopharm General Manager Gemma Budd commented, “This milestone reflects the significant investment Aptar Pharma has made in building a high-quality, GMP-compliant organization and the commitment of the Nanopharm team to operating in line with applicable regulatory requirements. The MHRA certification strengthens Nanopharm’s position as a trusted partner for companies developing complex inhaled and nasal medicines and further supports Aptar Pharma Services’ integrated offering for pharmaceutical companies worldwide.”
Aptar Group VP, Quality & Regulatory Compliance, Global Pharma, Manjiri Kaundinya said, “Alongside Aptar Pharma’s FDA-inspected cGMP analytical facilities in North America – Gateway Analytical and Aptar Pharma Services, Inc., Boonton – this expanded presence in Europe reinforces Aptar’s commitment to quality and regulatory compliance, not only within its manufacturing operations but also across the services it provides to its pharmaceutical customers.”
Read the Aptar Pharma press release
